Literature DB >> 19322922

Positional effect of mutations in 5'UTR of hepatitis C virus 4a on patients' response to therapy.

Mostafa-K El Awady1, Hassan-M Azzazy, Ahmed-M Fahmy, Sherif-M Shawky, Noha-G Badreldin, Samar-S Yossef, Moataza-H Omran, Abdel-Rahman-N Zekri, Said-A Goueli.   

Abstract

AIM: To investigate the effects of mutations in domain III of the hepatitis C virus (HCV) internal ribosome entry sequences (IRES) on the response of chronic HCV genotype 4a patients to interferon therapy.
METHODS: HCV RNA was extracted from 19 chronic HCV 4a patients receiving interferon/ribavirin therapy who showed dramatic differences in their response to combination therapy after initial viral clearance. IRES domain III was cloned and 15 clones for each patient were sequenced. The obtained sequences were aligned with genotype 4a prototype using the ClustalW program and mutations scored. Prediction of stem-loop secondary structure and thermodynamic stability of the major quasispecies in each patient was performed using the MFOLD 3.2 program with Turner energies and selected constraints on base pairing.
RESULTS: Analysis of RNA secondary structure revealed that insertions in domain III altered Watson-Crick base pairing of stems and reduced molecular stability of RNA, which may ultimately reduce binding affinity to ribosomal proteins. Insertion mutations in domain III were statistically more prevalent in sustained viral response patients (SVR, n = 14) as compared to breakthrough (BT, n = 5) patients.
CONCLUSION: The influence of mutations within domain III on the response of HCV patients to combination therapy depends primarily on the position, but not the frequency, of these mutations within IRES domain III.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19322922      PMCID: PMC2665143          DOI: 10.3748/wjg.15.1480

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  23 in total

1.  Mfold web server for nucleic acid folding and hybridization prediction.

Authors:  Michael Zuker
Journal:  Nucleic Acids Res       Date:  2003-07-01       Impact factor: 16.971

2.  A prospect for pharmacogenomics in the interferon therapy of chronic viral hepatitis.

Authors:  Shiou-Hwei Yeh; Ding-Shinn Chen; Pei-Jer Chen
Journal:  J Antimicrob Chemother       Date:  2003-07-01       Impact factor: 5.790

3.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.

Authors:  Q L Choo; G Kuo; A J Weiner; L R Overby; D W Bradley; M Houghton
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

4.  The pathway of HCV IRES-mediated translation initiation.

Authors:  Geoff A Otto; Joseph D Puglisi
Journal:  Cell       Date:  2004-10-29       Impact factor: 41.582

5.  Quasispecies as predictive factor of rapid, early and sustained virological responses in chronic hepatitis C, genotype 1, treated with peginterferon-ribavirin.

Authors:  Javier Salmerón; Jorge Casado; Paloma Muñoz de Rueda; Victor Lafuente; Moises Diago; Manuel Romero-Gómez; Angel Palacios; Josefa León; Ana Gila; Rosa Quiles; Luis Rodriguez; Angeles Ruiz-Extremera
Journal:  J Clin Virol       Date:  2008-01-24       Impact factor: 3.168

6.  Mechanism of ribosome recruitment by hepatitis C IRES RNA.

Authors:  J S Kieft; K Zhou; R Jubin; J A Doudna
Journal:  RNA       Date:  2001-02       Impact factor: 4.942

7.  Crystal structure of an RNA tertiary domain essential to HCV IRES-mediated translation initiation.

Authors:  Jeffrey S Kieft; Kaihong Zhou; Angie Grech; Ronald Jubin; Jennifer A Doudna
Journal:  Nat Struct Biol       Date:  2002-05

8.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

Review 9.  Targeting internal ribosome entry site (IRES)-mediated translation to block hepatitis C and other RNA viruses.

Authors:  Asim Dasgupta; Saumitra Das; Raquel Izumi; Arun Venkatesan; Bhaswati Barat
Journal:  FEMS Microbiol Lett       Date:  2004-05-15       Impact factor: 2.742

Review 10.  Structural biology of hepatitis C virus.

Authors:  François Penin; Jean Dubuisson; Felix A Rey; Darius Moradpour; Jean-Michel Pawlotsky
Journal:  Hepatology       Date:  2004-01       Impact factor: 17.425

View more
  16 in total

1.  Frequency of nucleotide sequence variations in the internal ribosome entry site region of hepatitis C virus RNA isolated from responding and non-responding patients with hepatitis C virus genotype 3 infection.

Authors:  Anzar Ashraf; Anita Chakravarti; Priyamvada Roy; Premashish Kar; Oves Siddiqui
Journal:  Virusdisease       Date:  2016-08-06

2.  A Single-step Multiplex Quantitative Real Time Polymerase Chain Reaction Assay for Hepatitis C Virus Genotypes.

Authors:  Akanksha Singh; Dhananjay Singh Mankotia; Mohammad Irshad
Journal:  J Transl Int Med       Date:  2017-03-31

Review 3.  Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C.

Authors:  Shinya Maekawa; Nobuyuki Enomoto
Journal:  J Gastroenterol       Date:  2009       Impact factor: 7.527

4.  A novel duplex real-time reverse transcriptase-polymerase chain reaction assay for the detection of hepatitis C viral RNA with armored RNA as internal control.

Authors:  Shuang Meng; Jinming Li
Journal:  Virol J       Date:  2010-06-07       Impact factor: 4.099

5.  Novel nucleotide and amino acid covariation between the 5'UTR and the NS2/NS3 proteins of hepatitis C virus: bioinformatic and functional analyses.

Authors:  Hung-Yu Sun; Nai-Ying Ou; Shainn-Wei Wang; Wen-Chun Liu; Ting-Fang Cheng; Shiou-Jiuan Shr; Koun-Tem Sun; Ting-Tsung Chang; Kung-Chia Young
Journal:  PLoS One       Date:  2011-09-28       Impact factor: 3.240

6.  Genetic Variability of Hepatitis C Virus (HCV) 5' Untranslated Region in HIV/HCV Coinfected Patients Treated with Pegylated Interferon and Ribavirin.

Authors:  Iwona Bukowska-Ośko; Agnieszka Pawełczyk; Karol Perlejewski; Natalia Kubisa; Kamila Caraballo Cortés; Magdalena Rosińska; Rafał Płoski; Maria Fic; Justyna Kaźmierczak; Marta Popiel; Piotr Ząbek; Andrzej Horban; Marek Radkowski; Tomasz Laskus
Journal:  PLoS One       Date:  2015-05-01       Impact factor: 3.240

Review 7.  Role of viral and host factors in interferon based therapy of hepatitis C virus infection.

Authors:  Muhammad Imran; Sobia Manzoor; Javed Ashraf; Madiha Khalid; Muqddas Tariq; Hafiza Madeha Khaliq; Sikandar Azam
Journal:  Virol J       Date:  2013-10-01       Impact factor: 4.099

8.  Regulation of Translational Efficiency by Disparate 5' UTRs of PPARgamma Splice Variants.

Authors:  Shawn McClelland; Roopali Shrivastava; Jheem D Medh
Journal:  PPAR Res       Date:  2009-11-23       Impact factor: 4.964

9.  In vitro inhibition of hepatitis C virus by antisense oligonucleotides in PBMC compared to hepatoma cells.

Authors:  Samar Samir Youssef; Ahmed Mohamed Fahmy; Moataza Hassan Omran; Amr Saad Mohamed; Mohamed Ali El Desouki; Mostafa K El-Awady
Journal:  Biomed Res Int       Date:  2014-06-01       Impact factor: 3.411

Review 10.  Establishment of chronic hepatitis C virus infection: translational evasion of oxidative defence.

Authors:  Shiu-Wan Chan
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.